Susan Pandya

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

Geoffrey I. Shapiro, Katherine M. Bell‐McGuinn, Julian R. Molina et al. · Clinical Cancer Research · 2015 · 117 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

Geoffrey I. Shapiro, Patricia LoRusso, Eunice L. Kwak et al. · Investigational New Drugs · 2019 · 92 citations

Medicine, Oncology, Pharmacology +12

A phase 2 study of dalantercept, an activin receptor‐like kinase‐1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Antonio Jimeno, Marshall R. Posner, Lori J. Wirth et al. · Cancer · 2016 · 42 citations · Full text

Medicine, Oncology, Pharmacology +15

ACTR-46. AG-120, A FIRST-IN-class MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: UPDATED RESULTS FROM THE PHASE 1 NON-ENHANCING GLIOMA POPULATION

Ingo K. Mellinghoff, Mehdi Touat, Elizabeth A. Maher et al. · Neuro-Oncology · 2017 · 34 citations · Full text

Medicine, Oncology, Pharmacology +17

ACTR-46. AG120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: RESULTS FROM THE PHASE 1 GLIOMA EXPANSION COHORTS

Ingo K. Mellinghoff, Mehdi Touat, Elizabeth A. Maher et al. · Neuro-Oncology · 2016 · 20 citations · Full text

Medicine, Oncology, Pharmacology +17